Corcept Therapeutics Inc. R (HTD.DU) Q1 FY2026 earnings call transcript
Corcept Therapeutics reported its Q1 FY2026 earnings, with revenues reaching $164.9 million, an increase from the previous year. Despite the revenue growth, the company posted a net loss of $31.8 million for the quarter. Management revised its full-year revenue guidance upwards to $950 million–$1.05 billion, attributing this optimism to strong prescription growth, positive clinical trial results, and a successful launch of its oncology drug, Lifyorli.
After a $1.13M September sale, Corcept (CORT) officer proposes another share sale.
Corcept Therapeutics (CORT) officer Joseph D. Lyon has proposed selling 10,000 common shares with an aggregate market value of $1,152,300.00 on October 1, 2026, through Stifel Nicolaus. This follows previous sales by Lyon of 1,540 shares in August and 10,000 shares in September 2026, totaling over $1.3 million. The shares originate from a stock option exercise, and the filing provides details on the transaction and relevant SEC regulations.
Corcept Therapeutics (CORT) business chief gifts shares; two custodial accounts acquire 5,000 each
Corcept Therapeutics' Chief Business Officer, Gary Charles Robb, reported gifting 17,100 common shares on September 24, 2026, which reduced his direct holdings to 14,056 shares. On the same date, two separate transactions of 5,000 shares each were acquired in custodial accounts for his children under the Uniform Transfers to Minors Act. Robb also indirectly held 39,716 shares through a revocable trust, for which he is the trustee.
Corcept Therapeutics options: a long strangle signals volatility bet ahead of 2027
A significant long strangle option trade on Corcept Therapeutics (CORT) suggests a high-conviction volatility bet ahead of January 2027. This strategy, involving simultaneous buying of out-of-the-money call and put options, indicates expectations of a substantial price move in either direction, driven by potential catalysts like the performance of its oncology drug LIFYORLI or regulatory updates for relacorilant. Despite a concurrent drop in implied volatility, the trade highlights a market anticipating binary outcomes for the stock.
Corcept Therapeutics’ oncology president sells $29,842 in stock
Roberto Wandenkolk Vieira, Corcept Therapeutics' President of Oncology, sold 296 shares of company stock worth $29,842 on September 16, 2026. This transaction occurred under a pre-arranged 10b5-1 trading plan and follows a significant 209% surge in CORT stock over the past six months. Despite the stock's performance and recent strong Q2 2026 results, InvestingPro analysis suggests Corcept Therapeutics is overvalued relative to its Fair Value.
Is Corcept Therapeutics (CORT) Undervalued After CHMP Backing For Relacorilant?
Corcept Therapeutics (CORT) is gaining attention after the European Medicines Agency’s CHMP supported the approval of relacorilant for platinum-resistant ovarian cancer, leading to a significant rally in its stock price. Despite recent gains, the company is considered 18% undervalued with a fair value of $141, driven by an expanding addressable patient pool for hypercortisolism and demographic shifts. Investors are advised to independently assess the company's financial health and risks, including potential generic erosion of Korlym or regulatory setbacks for relacorilant, before making investment decisions.
Corcept Therapeutics Announces New Endocrinology Division President
Corcept Therapeutics announced that Sean Maduck, President of its Endocrinology division, will resign on October 1, 2026, after 14 years. Justin Gunn, who previously led the build-out of the field sales and training for Lifyorli, will succeed him. Maduck will continue as a senior commercial adviser for one year.
Does EU Ovarian Cancer Backing Change The Bull Case For Corcept Therapeutics Stock?
The European Medicines Agency (CHMP) has recommended approval for Corcept Therapeutics' relacorilant for platinum-resistant ovarian cancer, expanding its commercial potential beyond the US. This move supports Corcept's strategy to diversify its product portfolio and reduce reliance on its existing Korlym franchise. The company's future success now hinges on effective commercialization of relacorilant in Europe and managing existing product pressures.
Corcept Announces Planned Leadership Transition
Corcept Therapeutics Incorporated announced a leadership transition in its Endocrinology division. Sean Maduck will retire as President, Endocrinology, and Justin Gunn will succeed him, effective October 1. Mr. Maduck will remain as a senior commercial advisor to ensure a smooth transition.
Corcept Names Justin Gunn President of Endocrinology as Sean Maduck Retires
Corcept Therapeutics Inc. has appointed Justin Gunn as President of its Endocrinology division, succeeding Sean Maduck who is retiring after 14 years but will remain a senior commercial advisor. Gunn, who previously led sales and commercial learning for Corcept's Oncology division, will assume the new role on October 1, 2026, and report to CEO Joseph K. Belanoff. This transition aims to leverage Gunn's commercial launch experience as Corcept expands its reach in Cushing's syndrome treatment and continues its research into cortisol modulation.
Corcept Therapeutics' Sean Maduck to Resign as President of Corcept Endocrinology, to Serve as Consultant
Sean Maduck will resign as President of Corcept Endocrinology effective October 1, 2026, and will transition to a consultant role for Corcept Therapeutics through a one-year agreement. His consulting services will include advising the CEO and executive management, and he will receive $57,000 per month for his services, with stock options continuing to vest as per the original schedule.
Corcept Therapeutics (CORT) oncology president sells shares under 10b5-1 plan
Corcept Therapeutics (CORT) reported that Roberto Wandenkolk Vieira, President of Oncology, sold 296 shares of common stock at $100.82 per share on September 16, 2026. This transaction was conducted under a Rule 10b5-1 trading plan. After the sale, Vieira directly held 3,946 shares, which includes 1,347 unvested restricted stock awards.
Corcept Therapeutics (CORT) Dropped, So What Is Behind The Latest Attention?
Corcept Therapeutics (CORT) is gaining attention after European regulators advanced its lead oncology asset towards potential approval for platinum-resistant ovarian cancer. Despite recent short-term share price drops, the company shows strong long-term momentum. The market currently views Corcept as undervalued, with a fair value estimate of $141, driven by expanding patient pools and anticipated regulatory approvals for its therapies, though patent litigation and single-product dependence pose risks.
Corcept Therapeutics Inc (CORT) Stock Price, Quote, News & History
This article provides a comprehensive overview of Corcept Therapeutics Inc (CORT) stock, including its current price, key statistics, recent news, financial data, analyst trends, and valuation metrics. It highlights the company's focus on developing medications for severe metabolic, oncologic, and neuropsychiatric disorders by modulating the cortisol hormone. The document also includes an FAQ section answering common questions about purchasing CORT stock, its competitors, price targets, dividends, earnings, stock splits, and industry sector.
Corcept Therapeutics president Vieira sells $29,842 of stock
Roberto Wandenkolk Vieira, President of Oncology at Corcept Therapeutics Inc. (NASDAQ:CORT), sold 296 shares of company stock for $29,842 on September 16, 2026, as part of a pre-arranged 10b5-1 trading plan. Following the sale, Vieira beneficially owns 3,946 shares. Despite the stock being considered overvalued by InvestingPro, the company maintains "GOOD" financial health and recently reported strong Q2 2026 earnings and an increased full-year revenue outlook, prompting positive analyst reactions.
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
Corcept Therapeutics announced that the European Medicines Agency's CHMP has recommended EU marketing authorization for Lifyorli® (relacorilant) combined with nab-paclitaxel, for treating platinum-resistant ovarian cancer. This recommendation is based on positive Phase 2 and pivotal Phase 3 ROSELLA trial data showing improved progression-free and overall survival without additional safety concerns. The European Commission is expected to make a final approval decision in Q4 2026.
Corcept Grows to Mid-Cap on Institutional Support
Corcept (CORT) has shown significant growth, rising to mid-cap status due to strong institutional support and impressive financial performance. The company reported record revenue and net income in Q2 fiscal 2026, with shares increasing by 218% year-to-date. MoneyFlows data indicates substantial Big Money investor interest, driven by solid sales growth and estimated EPS increases, making CORT a long-term top-rated stock.
Form 144 | Corcept Therapeutics(CORT.US) Director Proposes to Sell 3.34 Million in Common Stocks
This article reports that a director at Corcept Therapeutics (CORT.US) is proposing to sell common stock valued at $3.34 million. The information is derived from a Form 144 filing, which indicates an insider's intent to sell restricted or controlled securities.
Corcept Therapeutics (CORT) director plans $3.34M stock sale
Corcept Therapeutics (CORT) director James N. Wilson has filed a Rule 144 notice to sell up to 30,000 shares of common stock, valued at approximately $3.34 million, through The Charles Schwab Corporation. These shares are related to stock option awards from February 24, 2026. Wilson also reported prior sales of 10,000 shares each in July and August 2026, totaling over $1.99 million.
Corcept Therapeutics (CORT) Short Interest & Short Float | Updated Sep 2026 $CORT
Corcept Therapeutics (CORT) had a short interest of 9.40 million shares as of August 31, 2026, representing 10.96% of its public float, a decrease of 3.07% from the prior report. The short interest ratio stands at 11.9 days to cover. This data indicates a slight reduction in bearish sentiment among investors, though the percentage of float shorted remains moderately high.
Corcept Therapeutics posts strong Q2 revenue, expanding Cushing's market and oncology growth drive optimism.
Corcept Therapeutics reported strong Q2 2026 revenue of $256.1 million, a 32% year-over-year increase, significantly boosted by the $47.6 million launch of its oncology drug, Lifyorli. The company is transitioning from a single-focus endocrine treatment to a multi-engine growth platform, with new studies indicating a larger market for Cushing's disease and a promising pipeline. Despite increased launch expenses, Corcept remains profitable, projecting a positive outlook for the latter half of 2026.
Corcept Therapeutics oncology president sells $6.46m in shares
Roberto Wandenkolk Vieira, President of Oncology at Corcept Therapeutics Inc. (NASDAQ:CORT), sold shares worth approximately $6.46 million and acquired additional shares between September 1 and September 2, 2026. These transactions, conducted under a 10b5-1 plan, occurred while the company's stock trades at $112.80, representing a 224% year-to-date surge. The report also highlights Corcept's strong Q2 2026 earnings and raised revenue outlook, leading to increased price targets from analysts.
Corcept Therapeutics (CORT) CFO adds shares via plan and restricted awards
Corcept Therapeutics (CORT) CFO Atabak Mokari engaged in routine equity transactions, acquiring 138 shares of common stock under a purchase plan and receiving 138 unvested restricted stock awards on September 1, 2026. Additionally, 102 shares were withheld on September 2, 2026, to cover tax withholding obligations related to the vesting of restricted stock units. These transactions are detailed in an SEC Form 4 filing, indicating mixed insider activity without open-market purchases or sales.
Corcept Therapeutics Insider Sold Shares Worth $6,460,766, According to a Recent SEC Filing
An insider at Corcept Therapeutics sold shares valued at $6,460,766, as reported in a recent SEC filing. The article provides details on the transaction and includes other recent news and financial information related to Corcept Therapeutics, such as earnings reports and analyst ratings. It also offers a company profile and market data for Corcept Therapeutics Incorporated.
Corcept president Sean Maduck sells $2.86m in stock
Corcept Endocrinology President Sean Maduck sold approximately $2.86 million worth of Corcept Therapeutics stock on September 1, 2026, as part of a pre-arranged trading plan. Despite the sale, Maduck also acquired shares through stock options and a company purchase plan. These transactions occurred while Corcept shares have seen a significant year-to-date surge, and recent company news indicates strong financial performance and positive analyst outlooks.
CORCEPT Therapeutics Officer Vieira Roberto Wandenkolk to Sell 75,295 Shares Including 74,999 Stock Options (NASDAQ: CORT)
CORCEPT Therapeutics officer Vieira Roberto Wandenkolk plans to sell 75,295 common shares of the company (NASDAQ: CORT), valued at approximately $8.34 million. The sale includes 74,999 shares from a stock-option exercise on February 1, 2024, and 296 shares from an employee stock purchase plan (ESPP) transaction on September 1, 2026. Stifel Nicolaus & Company Inc. will act as the broker for this transaction.
Corcept Therapeutics Director Kimberly Park Reports Stock Option Exercise and Sale in SEC Form 4 Filing
Corcept Therapeutics Director Kimberly Park recently exercised 30,000 stock options and sold 26,685 shares of the company's common stock. The transactions, detailed in an SEC Form 4 filing, occurred on August 26, 2026, with the shares sold at a weighted average price of $122.5471. Following these transactions, Park no longer directly holds common stock but retains 30,000 shares underlying a stock option expiring in 2029.
Corcept Therapeutics' Sean Maduck Executes Stock Option Exercise and Sells Shares Under 10b5-1 Plan
Sean Maduck, President of Corcept Endocrinology at Corcept Therapeutics (NASDAQ: CORT), exercised 30,955 stock options and subsequently sold an equivalent number of common shares on August 25, 2026. These transactions, valued at over $3.8 million, were executed under a pre-established 10b5-1 trading plan. After these sales, Maduck directly holds 9,755 shares, including unvested restricted stock awards, and retains 169,045 outstanding stock options.
$22M stock sale lined up at Corcept Therapeutics (NASDAQ: CORT)
An officer at Corcept Therapeutics (NASDAQ: CORT), Sean Maduck, plans to sell up to 175,000 shares of common stock valued at approximately $22 million, originating from stock option awards from 2017 and 2019. This proposed sale, managed by Stifel Nicolaus & Company Inc, follows several smaller sales by Maduck over the past three months. The filing indicates a neutral impact and sentiment for the company.
Corcept Therapeutics Stock Climbs 11% On A 6-Day Winning Streak
Corcept Therapeutics (CORT) stock has climbed 11% over 6 consecutive trading days, adding $1.2 billion to its market value, now at $13 billion. This recent surge contributes to a much larger gain of 104.8% over the past three months and 251.3% year-to-date in 2026. Despite its high P/E multiple and low operating margin, which are influenced by a single unprofitable quarter, the company's revenue growth of 16.0% over the last twelve months (with a 3-year average of 24.9%) outpaces the S&P 500.
Have Corcept Therapeutics Insiders Been Selling Stock?
Corcept Therapeutics' Chief Business Officer & Secretary, Gary Robb, recently sold US$1.2 million worth of shares, decreasing his holding by 11%. Over the last year, insiders have sold more shares than they bought, although an independent director did purchase US$3.3 million worth of shares at a significantly lower price. Despite the insider selling, insiders still own 11% of the company, valued at US$1.4 billion.
Corcept Therapeutics Stock 6-Day Winning Spree: Stock Climbs 11%
Corcept Therapeutics (NASDAQ: CORT) stock has experienced a significant uptrend, achieving a 6-day winning streak where its stock climbed by 11%. This consistent rise indicates strong positive momentum for the company's shares.
Have Corcept Therapeutics Insiders Been Selling Stock?
Corcept Therapeutics (NASDAQ:CORT) has seen recent insider selling, with Chief Business Officer & Secretary Gary Robb selling US$1.2m worth of shares. While there was a significant insider purchase by an independent director in the last year, it was at a much lower price, and overall, insiders have sold more shares than they bought. Despite high insider ownership, the recent selling activity might concern investors.
Truist assumes Corcept Therapeutics stock with buy rating on Cushing’s opportunity
Truist Securities initiated coverage on Corcept Therapeutics Inc. (NASDAQ:CORT) with a buy rating and a $164 price target, citing significant opportunity in Cushing's disease and the potential of Lifyorli for ovarian and other solid tumors. The firm projects higher peak adjusted sales for the Cushing's franchise than consensus and sees Lifyorli as a blockbuster drug. Corcept recently reported strong Q2 2026 revenues of $256.1 million, surpassing estimates and raising its full-year revenue outlook, leading to a raised price target from H.C. Wainwright as well.
Corcept Therapeutics(CORT.US) Director Sells US$12.25 Million in Common Stock
A director at Corcept Therapeutics (CORT.US) recently sold common stock valued at $12.25 million. This transaction indicates a significant insider sale from the company. The specific details of the sale would likely be found in a Form 4 filing.
NewEdge Wealth LLC Makes New $3.03 Million Investment in Corcept Therapeutics Incorporated $CORT
NewEdge Wealth LLC has invested $3.03 million in Corcept Therapeutics, acquiring 34,890 shares. This comes amidst other institutional investor activity and a generally positive analyst outlook, with a consensus "Moderate Buy" rating. Corcept Therapeutics reported strong quarterly results, exceeding analyst expectations for both revenue and earnings per share.
Corcept Therapeutics stock hits all-time high at 122.5 USD
Corcept Therapeutics (CORT) stock has reached an all-time high of $122.50, driven by strong financial performance, including a 32% increase in Q2 2026 revenue and an upward adjustment to its full-year revenue outlook. Analyst firms like H.C. Wainwright and Truist Securities have reiterated or initiated Buy ratings, highlighting the company's potential in Cushing's disease and anticipated approval of relacorilant. Despite being considered overvalued by InvestingPro, the stock has shown significant growth with a 72.71% increase over the past year and a 248% return in the last six months.
Corcept Therapeutics (CORT) director offloads stock under 10b5-1 plan
Corcept Therapeutics (CORT) director David L. Mahoney, through a family trust, sold 103,606 shares of company common stock on August 18, 2026. The sales, executed under a Rule 10b5-1 trading plan adopted on May 11, 2026, occurred at weighted average prices between $116.595 and $119.6775. Mahoney's indirect holdings also include 26,147 shares via The Black Dog Private Foundation and 1,133,539 shares through the family trust after the transaction.
Corcept Therapeutics (NASDAQ:CORT) Director Sells 103,606 Shares
Corcept Therapeutics Director David Mahoney sold 103,606 shares for approximately $12.25 million, reducing his stake by 8.37%. The company's shares are trading near a 52-week high, with a market capitalization of $13.09 billion and a high P/E ratio. Recent earnings exceeded expectations, and analysts maintain a "Moderate Buy" consensus with an average price target of $138.17.
Lisanti Capital Growth LLC Takes Position in Corcept Therapeutics Incorporated $CORT
Lisanti Capital Growth LLC has acquired 91,610 shares of Corcept Therapeutics (CORT) valued at approximately $7.97 million, making it their fifth-largest holding. Institutional investors collectively own 93.61% of the company, while analyst sentiment is largely positive despite a recent downgrade by Wolfe Research. The company reported strong Q2 earnings, surpassing revenue and EPS estimates, but insiders have sold a significant amount of stock in the last three months.
Truist Financial Initiates Corcept Therapeutics(CORT.US) With Buy Rating, Announces Target Price $164
Truist Financial has initiated coverage on Corcept Therapeutics (CORT.US) with a Buy rating. The financial institution also announced a target price of $164 for the pharmaceutical company's stock.
Corcept Therapeutics (NASDAQ:CORT) Director James Wilson Sells 10,000 Shares of Stock
Corcept Therapeutics Director James Wilson sold 10,000 shares of CORT stock for over $1.11 million, reducing his stake by 0.92%. The company recently exceeded Q2 earnings and revenue expectations, reporting $0.36 EPS against a $0.02 consensus and $256.15 million in revenue. Analyst sentiment remains largely positive with a "Moderate Buy" consensus, despite one recent downgrade.
Corcept (NASDAQ: CORT) director sells 10,000 shares under 10b5-1 plan
Corcept (NASDAQ: CORT) director James N. Wilson, through the James N. Wilson and Pamela D. Wilson Trust, reported the indirect sale of 10,000 shares of common stock on August 14, 2026. These sales were conducted in multiple open-market transactions at weighted average prices between approximately $110 and $113 per share, pursuant to a pre-established Rule 10b5-1 trading plan adopted on March 12, 2026. Wilson disclaims beneficial ownership of the trust's shares except to the extent of his pecuniary interest, while separate grantor retained annuity trusts maintain indirect holdings of 200,000 shares each.
Corcept (NASDAQ: CORT) director plans open-market sale of 103,606 shares
A director at Corcept Therapeutics Inc. (NASDAQ: CORT), David L. Mahoney, has filed a Form 144 notice indicating a planned open-market sale of 103,606 shares of common stock. The shares, valued at approximately $12.16 million, were acquired through open market purchases between May 2020 and April 2024. The proposed sale is set to occur on or after August 18, 2026, subject to Rule 144 conditions.
Truist Adjusts Price Target on Corcept Therapeutics to $164 From $50, Maintains Buy Rating
Truist has significantly raised its price target for Corcept Therapeutics (CORT) to $164 from $50, while reiterating a Buy rating on the stock. This adjustment follows several positive updates for Corcept, including strong Q2 2026 earnings, increased revenue guidance for the full year, and the resubmission of their NDA for the Cushing's Syndrome treatment, Relacorilant. The company is actively engaged in developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders, with a focus on modulating the effects of cortisol.
Truist assumes Corcept Therapeutics stock with buy rating on Cushing’s opportunity
Truist Securities has initiated coverage on Corcept Therapeutics Inc. (NASDAQ:CORT) with a buy rating and a price target of $164, citing the significant opportunity in Cushing's disease and the potential of its drug relacorilant. The firm also highlighted Lifyorli, which received early approval for ovarian cancer and is viewed as a blockbuster opportunity with potential expansion into other solid tumors. This positive outlook follows Corcept Therapeutics' strong second-quarter 2026 financial results, which saw a 32% revenue increase and a raised full-year revenue outlook.
Corcept Therapeutics stock soars 228% after FDA support and tariff news boost shares.
Corcept Therapeutics' stock surged 228% to $117.17, driven by FDA backing for its drug relacorilant, positive clinical trial results showing a 35% reduction in death risk, and President Trump's announcement of continued zero-percent tariffs on imported generic drugs until 2026. This significant increase boosted President Trump's disclosed holdings in the company and elevated Corcept's market capitalization to $12.67 billion. The rally reflects favorable regulatory and trade developments for the pharmaceutical company.
CORCEPT THERAPEUTICS INC SEC Filing (Aug 17, 2026)
This article reports on a Form 144 SEC filing by CORCEPT THERAPEUTICS INC (CORT) dated August 17, 2026. The filing indicates a proposed sale of 10,000 shares of common stock with an aggregate market value of $1,162,572. The shares were acquired on December 31, 2025, through equity compensation and are to be sold via Stifel Nicolaus & Company Inc.
113,200 Shares in Corcept Therapeutics Incorporated $CORT Purchased by Alberta Investment Management Corp
Alberta Investment Management Corp recently acquired 113,200 shares of Corcept Therapeutics (NASDAQ:CORT) for approximately $9.84 million, establishing a 0.10% stake in the company. Institutional investors collectively own 93.61% of Corcept, which reported strong quarterly earnings with EPS of $0.36 and revenue up 31.7% year-over-year. Analysts currently have a "Moderate Buy" rating for the stock, with an average price target of $119.17, although insiders have recently sold a significant number of shares.
Corcept Therapeutics (CORT) Stock Looks Discounted On Sales But Premium Priced On Broader Checks
Corcept Therapeutics (CORT) stock has seen significant returns over the past five years, but current valuations suggest it may be expensive. While its Price/Sales ratio appears discounted compared to a tailored model, it trades at a premium to the broader pharmaceutical industry, indicating mixed signals for investors. The article highlights both bull and bear cases, emphasizing the importance of future revenue and margin performance in light of clinical, regulatory, and legal risks.
